Aggrenox Related Published Studies
Well-designed clinical trials related to Aggrenox (Aspirin / Dipyridamole)
Use of aspirin associates with longer primary patency of hemodialysis grafts. [2011.04]
Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy. [2011.01]
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. [2011]
Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease. [2010.05.01]
Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. [2010.02]
Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: A randomized, single-blind, 30-day trial. [2008.02]
Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers. The AGgrenox versus Aspirin Therapy Evaluation (AGATE-Japan). [2008.01]
Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. [2005.03]
Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. [2005]
Acetaminophen in the treatment of headaches associated with dipyridamole-aspirin combination. [2004.09.28]
Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. [2004.09.24]
Aspirin in diabetic retinopathy. A systematic review. [2002.09]
Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure? [2002.07]
A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. [2002]
Aggrenox: a fixed-dose combination of aspirin and dipyridamole. [2000.11]
Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. [1998.09.15]
Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. [1997.01]
Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant. [1996.11.01]
Combined dipyridamole and aspirin pellet formulation for improved oral drug delivery. Part 2: In-vivo evaluation and stability. [1996.07]
Effects of low dose aspirin (50 mg/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents after internal mammary artery bypass grafting: patency and clinical outcome at 1 year. CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Prevention of Coronary Artery Bypass Graft Occlusion by Aspirin, Dipyridamole and Acenocoumarol/Phenprocoumon Study. [1994.11.01]
Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. [1994.10.01]
Effect of various antithrombotic regimens (aspirin, aspirin plus dipyridamole, anticoagulants) on the functional status of patients and grafts one year after coronary artery bypass grafting. [1994.08]
Secondary prevention of stroke: does dipyridamole add to aspirin? [1994]
Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS) [1994]
Placebo-controlled trial of enteric coated aspirin in coronary bypass graft patients. Effect on graft patency. [1993.09.20]
Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. [1993.07.31]
The role of dipyridamole in addition to low dose aspirin in the prevention of occlusion of coronary artery bypass grafts. [1992.12]
Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy. [1992.05.01]
Aspirin usage and its influence on femoro-popliteal vein graft patency. The Femoro-popliteal Bypass Trial Participants. [1992.03]
Effects of aspirin, dipyridamole, nifedipine and cavinton which act on platelet aggregation induced by different aggregating agents alone and in combination. [1992]
Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease. [1992]
[Treatment of unstable angina with dipyridamole combined with low doses of aspirin. A multicenter pilot double-blind controlled study] [1991.07]
Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. [1991.06.15]
A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group. [1991.05]
Effect of dipyridamole alone and in combination with aspirin on whole blood platelet aggregation, PGI2 generation, and red cell deformability ex vivo in man. [1991.03]
Effect of aspirin and dipyridamole treatment on prostacyclin production by human veins. [1990.04.15]
Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. [1990.02.15]
Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. [1990.01]
Effect of dipyridamole and aspirin on vein graft patency after coronary bypass operations. [1990]
Does low-dose aspirin prevent aortocoronary vein bypass graft occlusion? The Spanish Group for Aortocoronary Bypass Follow-up (GESIC Study). [1990]
Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. [1989.07.01]
A trial of dipyridamole and aspirin in the prevention of smoking-induced changes in platelets and endothelium in men with coronary artery disease. [1989.06.15]
Long term clinical outcome of coronary surgery and assessment of the benefit obtained with postoperative aspirin and dipyridamole. [1988.08]
Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. [1988.06.30]
Platelet deposition on human atherosclerotic lesions is decreased by low-dose aspirin in combination with dipyridamole. [1988.01]
[Dipyridamole and low-dose aspirin in patients with aortocoronary bypass--comparison with anticoagulation] [1987.10.24]
Well-designed clinical trials possibly related to Aggrenox (Aspirin / Dipyridamole)
Influence of Antiplatelet Therapy on Cerebral Micro-Emboli after Carotid Endarterectomy using Postoperative Transcranial Doppler Monitoring. [2007.08]
Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled trial with angiographic and clinical follow-up after myocardial infarction. [2007.01]
The action of dipyridamole to prevent thrombosis: practical implications for the treatment and prevention of stroke. [2006.05]
Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole. [2005.10]
Dipyridamole bioavailability in subjects with reduced gastric acidity. [2005.07]
Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. [2005.01]
Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers. [2005]
Enhanced antiplatelet effects of clopidogrel plus acetylsalicylic acid compared with acetylsalicylic acid alone or combined with extended-release dipyridamole in healthy volunteers. [2005]
Dipyridamole and headache--a pilot study of initial dose titration. [2004.08.30]
Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. [2003.10]
Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting. [2003.06]
Preventing stroke in patients with atrial fibrillation: current treatments and new concepts. [2003.03]
[Does early high dosage dipyridamole in prevention of secondary stroke induce cardiac events?] [2001.05]
Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). [2001.04]
Inhibition of thrombus formation by low-dose acetylsalicylic acid, dipyridamole, and their combination in a model of platelet-vessel wall interaction. [2001]
Plasma levels of C-reactive protein after coronary stent implantation. [2000.07]
Adjunctive intracoronary dipyridamole in the interventional treatment of small coronary arteries: a prospectively randomized trial. [2000.06]
Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: a prospective randomised trial. [2000.05]
Design of ESPRIT: an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group. [2000.03]
Rapid development of tolerance to dipyridamole-associated headaches. [1999.11]
[Intravenous dipyridamole in acute cerebral infarct. Is it efficacious?] [1999.07]
[Secondary prevention after ischemic cerebral infarct. The ESPRIT Study: low dose anticoagulation, combined therapy with acetylsalicylic acid/dipyridamole or monotherapy with acetylsalicylic acid?] [1999.04]
Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group. [1999.01]
[Long term effects of 50 mg acetylsalicylic acid alone and in combination with dipyridamole on platelet function after coronary bypass surgery] [1998.11]
[Effect of intracoronary dipyridamole administration on the incidence of restenosis after PTCA. A prospective randomized study] [1998.10.15]
Efficacy of antiplatelet treatment in hypertensive patients with TIA or stroke. [1998.08]
Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and stenosis severity. [1998.03.15]
[Prevention of vascular complications following cerebral ischemia of arterial origin; the ESPRIT trial: mild anticoagulant therapy, combination treatment with acetylsalicylic acid plus dipyridamole or treatment with acetylsalicylic acid alone?] [1998.02.07]
Risk factors and antiplatelet therapy in TIA and stroke patients. [1998.02.05]
European Stroke Prevention Study-2 results: serendipitous demonstration of neuroprotection induced by endogenous adenosine accumulation? [1998.01]
[Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study] [1997.12]
Rationale for low-molecular weight heparin in coronary stenting. [1997.11]
Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. [1997.07]
European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. [1997.06]
Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: impact on hemodynamic function and left ventricular performance. [1996.11.01]
[Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors] [1996.11]
[The changes of vasoactive intestinal peptide somatostatin and pancreatic polypeptide in blood and CSF of acute cerebral infarction patients and the effect of acupuncture on them] [1996]
[The effect of Taprostene on platelet activation and clinical course after percutaneous transluminal angioplasty] [1996]
Use of cumulative meta-analysis in the design, monitoring, and final analysis of a clinical trial: a case study. [1995.10]
Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. [1995.01]
Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism. [1995]
Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. [1994.05]
Factors influencing 1-year patency of coronary artery saphenous vein grafts. Studio Indobufene nel Bypass Aortocoronarico (SINBA). [1993.11]
Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event. [1993.07]
European Stroke Prevention Study (ESPS): antithrombotic therapy is also effective in the elderly. [1993.02]
[The effect of indobufen on aortocoronary bypass patency after 1 week and after 1 year] [1993]
Efficacy and safety of anticoagulant therapy started pre-operatively in preventing coronary vein graft occlusion. [1992.09]
Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. [1992.06]
[Comparative study of anticoagulant management after coronary artery bypass surgery--warfarin versus dipyridamole] [1992.04]
[The effect of low-dose acetylsalicylic acid on platelet aggregation parameters in vitro] [1992.04]
Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. [1992.04]
Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. [1991.11.30]
Antiplatelet therapy is effective in the prevention of stroke or death in women: subgroup analysis of the European Stroke Prevention Study (ESPS). [1991.10]
Liquid crystal thermography as a screening test for deep vein thrombosis in patients with cerebral infarction. [1991.10]
Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. [1991.08.08]
|
